Titration Study of ABX-1431

Phase 1 Completed 39 enrolled Abide Therapeutics

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.

Timeline

Start: 2017-10-02
Primary completion: 2019-05-07
Completion: 2019-05-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABX-1431	Small molecule	2 mg	Oral
Subject	ABX-1431	Small molecule	10 mg	Oral
Subject	ABX-1431	Small molecule	50 mg	Oral

Titration Study of ABX-1431

Summary

Timeline

Drugs

Indications